“This is a significant penetration only seven months after commercial availability,” said Lauren Sabella, vice-president of commercial operations.
Ampyra (dalfampridine) is the first oral treatment prescribed to improve walking in patients with MS.
Are neurologists and patients readily embracing Ampyra, as claimed by management claim? Read More at BNET….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.